A Real-World Perspective of Quadruple Treatment Patterns for 1L Multiple Myeloma Patients across North and South America, Europe and Asia
Author(s)
Tatiana Checchia, MBA1, Kelechi Emeanuru, MPH2, Mariah Baltezegar, MBA2, Luis Arthur Pelloso, MD, PhD3.
1Thermo Fisher Scientific, Prague, Czech Republic, 2Thermo Fisher Scientific, Waltham, MA, USA, 3Thermo Fisher Scientific, Sao Paulo, Brazil.
1Thermo Fisher Scientific, Prague, Czech Republic, 2Thermo Fisher Scientific, Waltham, MA, USA, 3Thermo Fisher Scientific, Sao Paulo, Brazil.
Presentation Documents
OBJECTIVES: Recent combination therapies like quadruple therapy (QD) have become the preferred first line (1L) treatment option for Mm patients. The objective of this study is to identify and examine QD treatment patterns amongst 1L Mm patients across different countries in the top ten markets (Brazil, Mexico, United States, France, Germany, Italy, Spain United Kingdom, China, and Japan).
METHODS: Patients who received at least one line of therapy were identified through OncoLocator™; a real-time data collection tool, to examine treatment patterns reported by Healthcare Providers (HCPs). Data was collected on 1L patients from December 2022 to November 2024 that were treated with a drug combination that includes a proteasome inhibitor, immunomodulatory drug, steroid and antiCD38.
RESULTS: A total of 4,356 patients were included in the cohort, with an average of 435 patients per country. Amongst 1L patients, 65% (n=2,811) were SCT eligible and 35% (n=1,545) were SCT ineligible. Overall QD treatment use was highest in France (89%), Germany (82%), Italy (63%), UK (61%), US (39%) then Japan (27%). The use of D-RVd (Daratumumab + lenalidomide + bortezomib + dexamethasone), was predominant in France (71%), US (30%) and Spain (25%); while D-VTd (thalidomide) was the preferred regimen in UK (56%), Italy (52%), Germany (42%) and Japan (17%). The lowest adoption of QD treatment was in Mexico (34%), Brazil (18%) and China (1%).
CONCLUSIONS: Contemporary real-world data on QD trends reflect an evolving landscape, especially with treatment patterns for SCT-eligible patients across the US and EU regions. However, additional assessments should be conducted on the use of QDs as adoption increases across various countries.
METHODS: Patients who received at least one line of therapy were identified through OncoLocator™; a real-time data collection tool, to examine treatment patterns reported by Healthcare Providers (HCPs). Data was collected on 1L patients from December 2022 to November 2024 that were treated with a drug combination that includes a proteasome inhibitor, immunomodulatory drug, steroid and antiCD38.
RESULTS: A total of 4,356 patients were included in the cohort, with an average of 435 patients per country. Amongst 1L patients, 65% (n=2,811) were SCT eligible and 35% (n=1,545) were SCT ineligible. Overall QD treatment use was highest in France (89%), Germany (82%), Italy (63%), UK (61%), US (39%) then Japan (27%). The use of D-RVd (Daratumumab + lenalidomide + bortezomib + dexamethasone), was predominant in France (71%), US (30%) and Spain (25%); while D-VTd (thalidomide) was the preferred regimen in UK (56%), Italy (52%), Germany (42%) and Japan (17%). The lowest adoption of QD treatment was in Mexico (34%), Brazil (18%) and China (1%).
CONCLUSIONS: Contemporary real-world data on QD trends reflect an evolving landscape, especially with treatment patterns for SCT-eligible patients across the US and EU regions. However, additional assessments should be conducted on the use of QDs as adoption increases across various countries.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HSD81
Topic
Health Service Delivery & Process of Care
Disease
SDC: Oncology